Showing results (1-10 of 51) with videos related to
Sort By:
Pageof 6
European Heart Journal|September 21, 2022
The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertaintiesJurrien Ten Berg, Bianca Rocca, Dominick J Angiolillo, et al.Biomedicines|September 28, 2024
Current and Future Roles of Glycoprotein IIb-IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial InfarctionGiuseppe De Luca, Ashley Verburg, Arnoud Van't Hof, et al.Heart (British Cardiac Society)|January 5, 2024
Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular diseaseMaria C Castelijns, Steven H J Hageman, Martin Teraa, et al.European Heart Journal|November 10, 2025
Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?Mattia Galli, Jurrien Ten Berg, Marco Valgimigli, et al.Heart (British Cardiac Society)|June 11, 2015
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrelPetr Widimsky, Zuzana Motovska, Leonardo Bolognese, et al.European Heart Journal. Acute Cardiovascular Care|June 21, 2017
Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trialTomasz Rakowski, Dariusz Dudek, Arnoud van 't Hof, et al.International Journal of Cardiology|March 21, 2016
Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trialSinem Kilic, Arnoud W J Van't Hof, Jurrien Ten Berg, et al.American Heart Journal|November 7, 2015
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) studyDariusz Dudek, Artur Dziewierz, Petr Widimsky, et al.Journal of the American College of Cardiology|October 29, 2011
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant dataSomjot S Brar, Jurrien ten Berg, Rossella Marcucci, et al.European Heart Journal. Acute Cardiovascular Care|August 8, 2015
ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudyArnoud Van't Hof, Francesco Giannini, Jurrien Ten Berg, et al.Pageof 6